SCHEMBL1372978

SCHEMBL1372978

COc1ccc2c(c1)CCC(C(O)C(=O)O)C2=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP24A1 Q07973 6/20 0.54
CYP26A1 O43174 3/20 0.54
CYP27A1 Q02318 3/20 0.52
CYP19A1 P11511 1/20 0.51
DRD2 P14416 2/20 0.48
HTR2A P28223 2/20 0.48
HTR2C P28335 2/20 0.48
HTR2B P41595 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
METAP1 P53582 2/20 0.42
ACHE P22303 1/20 0.42
MIF P14174 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13639788 0.84 CYP24A1 (0.54) CYP24A1CYP26A1CYP27A1CYP19A1DRD2
SCHEMBL16588432 0.83 KDM4E (0.41) CYP24A1CYP26A1CYP27A1CYP19A1KDM4E
SCHEMBL12148265 0.80 CYP24A1 (0.49) CYP24A1CYP26A1CYP27A1CYP19A1DRD2
SCHEMBL14061905 0.80 CYP24A1 (0.52) CYP24A1CYP26A1CYP27A1CYP19A1DRD2
SCHEMBL4622848 0.79 CYP24A1 (0.58) CYP24A1CYP26A1CYP27A1CYP19A1DRD2
SCHEMBL10388746 0.76 KDM4E (0.57) CYP19A1DRD2HTR2AHTR2CHTR2B
SCHEMBL13039619 0.76 DRD2 (0.60) CYP24A1CYP26A1CYP27A1CYP19A1DRD2
SCHEMBL4621871 0.75 CYP24A1 (0.68) CYP24A1CYP26A1CYP27A1CYP19A1METAP1
SCHEMBL14061902 0.75 CYP24A1 (0.60) CYP24A1CYP26A1CYP27A1CYP19A1METAP1
SCHEMBL630841 0.75 ACHE (0.58) CYP24A1CYP26A1CYP27A1CYP19A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502918-B1 Pyridazinone Derivatives CEPHALON INC (US) 2015-03-25 EP disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-20140142088-A1 PYRIDAZINONE DERIVATIVES CEPHALON, INC. (US) 2014-05-22 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-8673916-B2 Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives CEPHALON, INC. (US) 2014-03-18 US disclosed
US-8586588-B2 Aryl pyridazinone derivatives and their use as H3 receptor ligands CEPHALON, INC. (US) 2013-11-19 US disclosed
US-8586588-B2 Aryl pyridazinone derivatives and their use as H3 receptor ligands CEPHALON, INC. (US) 2013-11-19 US disclosed
EP-2069312-B1 PYRIDIZINONE DERIVATIVES CEPHALON INC (US) 2012-11-07 EP disclosed
US-20100280007-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-11-04 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
US-20100273779-A1 Pyridazinone Derivatives CEPHALON, INC. (US) 2010-10-28 US disclosed
EP-2069312-A2 PYRIDIZINONE DERIVATIVES Cephalon, Inc. (US) 2009-06-17 EP disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed
US-20080027041-A1 Pyridizinone derivatives CEPHALON, INC. (US) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027041-A1 Pyridizinone derivatives H1-5, H1-3, H1-4 CYP24A1 624/4885CYP26A1 580/4885CYP27A1 1814/4885
US-20100280007-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 CYP24A1 821/4885CYP26A1 239/4885CYP27A1 1096/4885
US-20140142088-A1 PYRIDAZINONE DERIVATIVES HRH3, HNMT, HRH4 CYP24A1 844/4885CYP26A1 241/4885CYP27A1 1055/4885
US-20100273779-A1 Pyridazinone Derivatives HRH3, HNMT, HRH4 CYP24A1 821/4885CYP26A1 239/4885CYP27A1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.